117 related articles for article (PubMed ID: 1333824)
1. Towards an understanding of the mode of action of Bacillus Calmette-Guérin-therapy in bladder cancer treatment, especially with regard to the role of fibronectin.
van der Sloot E; Kuster S; Böhle A; Braun J; Wood WG
Eur J Clin Chem Clin Biochem; 1992 Sep; 30(9):503-11. PubMed ID: 1333824
[TBL] [Abstract][Full Text] [Related]
2. Effects of isoniazid (INH) on the BCG-induced local immune response after intravesical BCG therapy for superficial bladder cancer.
Stassar MJ; Vegt PD; Steerenberg PA; van der Meijden AP; Meiring HD; Dessens-Kroon M; Geertzen HG; den Otter W
Urol Res; 1994; 22(3):177-84. PubMed ID: 7992464
[TBL] [Abstract][Full Text] [Related]
3. Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin.
Ratliff TL; Palmer JO; McGarr JA; Brown EJ
Cancer Res; 1987 Apr; 47(7):1762-6. PubMed ID: 3545453
[TBL] [Abstract][Full Text] [Related]
4. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
Zlotta AR; Drowart A; Van Vooren JP; de Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
J Urol; 1997 Feb; 157(2):492-8. PubMed ID: 8996341
[TBL] [Abstract][Full Text] [Related]
5. Urinary fibronectin levels in patients treated with intravesical bacillus Calmette-Guérin for superficial bladder cancer.
Danişman A; Bulut K; Kukul E; Ozen I; Sevük M
Urol Int; 2000; 64(4):198-201. PubMed ID: 10895085
[TBL] [Abstract][Full Text] [Related]
6. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
[TBL] [Abstract][Full Text] [Related]
7. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer.
De Boer EC; De Jong WH; Steerenberg PA; Aarden LA; Tetteroo E; De Groot ER; Van der Meijden AP; Vegt PD; Debruyne FM; Ruitenberg EJ
Cancer Immunol Immunother; 1992; 34(5):306-12. PubMed ID: 1540977
[TBL] [Abstract][Full Text] [Related]
8. The fate of bacillus Calmette-Guerin after intravesical instillation.
Durek C; Richter E; Basteck A; Rüsch-Gerdes S; Gerdes J; Jocham D; Böhle A
J Urol; 2001 May; 165(5):1765-8. PubMed ID: 11342972
[TBL] [Abstract][Full Text] [Related]
9. Evolution of cellular and humoral response against Tuberculin and antigen 85 complex during intravesical treatment with BCG of superficial bladder cancer.
Zlotta A; Drowart A; van Vooren JP; Simon J; Schulman CC; Huygen K
Acta Urol Belg; 1994 Sep; 62(3):63-8. PubMed ID: 7976857
[TBL] [Abstract][Full Text] [Related]
10. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
[TBL] [Abstract][Full Text] [Related]
11. Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis.
de Boer EC; de Jong WH; van der Meijden AP; Steerenberg PA; Witjes F; Vegt PD; Debruyne FM; Ruitenberg EJ
Urol Res; 1991; 19(1):45-50. PubMed ID: 2028562
[TBL] [Abstract][Full Text] [Related]
12. Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors.
Hudson MA; Yuan JJ; Catalona WJ; Ratliff TL
J Urol; 1990 Dec; 144(6):1362-4. PubMed ID: 2231927
[TBL] [Abstract][Full Text] [Related]
13. Elevated urinary fibronectin levels after transurethral resection of bladder tumour: a possible role in patients failing therapy with bacillus Calmette-Guérin.
Laufer M; Kaver I; Sela B; Matzkin H
BJU Int; 1999 Sep; 84(4):428-32. PubMed ID: 10468755
[TBL] [Abstract][Full Text] [Related]
14. Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guérin (BCG) in patients with superficial bladder cancer.
Zlotta AR; Drowart A; Huygen K; De Bruyn J; Shekarsarai H; Decock M; Pirson M; Jurion F; Palfliet K; Denis O; Mascart F; Simon J; Schulman CC; Van Vooren JP
Clin Exp Immunol; 1997 Jul; 109(1):157-65. PubMed ID: 9218839
[TBL] [Abstract][Full Text] [Related]
15. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
[TBL] [Abstract][Full Text] [Related]
16. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
[TBL] [Abstract][Full Text] [Related]
17. Fibronectin expression on surgical specimens correlated with the response to intravesical bacillus Calmette-Guerin therapy.
Fleischmann JD; Park MC; Hassan MO
J Urol; 1993 Feb; 149(2):268-71. PubMed ID: 8426398
[TBL] [Abstract][Full Text] [Related]
18. Bacillus Calmette-Guérin interacts with the carboxyl-terminal heparin binding domain of fibronectin: implications for BCG-mediated antitumor activity.
Cheng DL; Shu WP; Choi JC; Margolis EJ; Droller MJ; Liu BC
J Urol; 1994 Oct; 152(4):1275-80. PubMed ID: 8072119
[TBL] [Abstract][Full Text] [Related]
19. Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndrome analysis.
Jackson AM; Ivshina AV; Senko O; Kuznetsova A; Sundan A; O'Donnell MA; Clinton S; Alexandroff AB; Selby PJ; James K; Kuznetsov VA
J Urol; 1998 Mar; 159(3):1054-63. PubMed ID: 9474231
[TBL] [Abstract][Full Text] [Related]
20. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]